Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 12/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 5/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328644 | 0.82 | HTT (0.39) | GHSRACACB | |
| SCHEMBL23328642 | 0.82 | HTT (0.39) | GHSRACACB | |
| SCHEMBL23328643 | 0.81 | HTT (0.47) | GHSRALDH1A1ACACB | |
| SCHEMBL31260259 | 0.81 | NR4A1 (0.50) | GHSRALDH1A1TGFBR1ACVR1KCNH2 | |
| SCHEMBL12354672 | 0.80 | ACACB (0.42) | ALDH1A1ACACB | |
| SCHEMBL12354673 | 0.78 | ACACB (0.45) | ALDH1A1ACACB | |
| SCHEMBL9224742 | 0.76 | DRD2 (0.56) | GHSRALDH1A1 | |
| SCHEMBL8343748 | 0.76 | ALDH1A1 (0.58) | ALDH1A1 | |
| SCHEMBL12445276 | 0.76 | DRD2 (0.56) | GHSRALDH1A1 | |
| SCHEMBL20883659 | 0.76 | HTR3A (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | GHSR 140/4885ALDH1A1 748/4885TGFBR1 126/4885 |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | FGFR1, FGFR4, FGFR2 | GHSR 139/4885ALDH1A1 642/4885TGFBR1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.